Citation Impact
Citing Papers
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Transcriptional regulation of macrophage polarization: enabling diversity with identity
2011 Standout
AGEs and Diabetic Retinopathy
2010
Rosiglitazone and Delayed Onset of Proliferative Diabetic Retinopathy
2008
A Systematic Comparison of the Properties of Clinically Used Angiotensin II Type 1 Receptor Antagonists
2013
Pioglitazone and cardiovascular risk. A comprehensive meta‐analysis of randomized clinical trials
2008
PPARγ Activation Primes Human Monocytes into Alternative M2 Macrophages with Anti-inflammatory Properties
2007
Diabetic retinopathy
2010 Standout
Independent β-Arrestin2 and Gq/Protein Kinase Cζ Pathways for ERK Stimulated by Angiotensin Type 1A Receptors in Vascular Smooth Muscle Cells Converge on Transactivation of the Epidermal Growth Factor Receptor
2009 StandoutNobel
Inflammation and metabolic disorders
2006 StandoutNature
Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial
2006
Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease
2006
Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein
2007
Mechanisms linking obesity with cardiovascular disease
2006 StandoutNature
A guide to immunometabolism for immunologists
2016 Standout
Pro-resolving lipid mediators are leads for resolution physiology
2014 StandoutNature
Physiology and Neurobiology of Stress and Adaptation: Central Role of the Brain
2007 Standout
Macrophages in the Pathogenesis of Atherosclerosis
2011 Standout
Atherosclerosis: current pathogenesis and therapeutic options
2011 Standout
Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators
2008 Standout
Direct antiatherosclerotic effects of PPAR agonists
2008
Inflammation and insulin resistance
2006 Standout
Type 2 diabetes as an inflammatory disease
2011 Standout
Macrophage-specific PPARγ controls alternative activation and improves insulin resistance
2007 StandoutNature
Adipokines in inflammation and metabolic disease
2011 Standout
Obesity, inflammation, and atherosclerosis
2009
Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association
2021 Standout
Endoplasmic Reticulum Stress and the Inflammatory Basis of Metabolic Disease
2010 Standout
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
2013 Standout
A New Perspective on Therapeutic Inhibition of Advanced Glycation in Diabetic Microvascular Complications: Common Downstream Endpoints Achieved Through Disparate Therapeutic Approaches?
2009
Peroxisome proliferator–activated receptor γ agonists for the Prevention of Adverse events following percutaneous coronary Revascularization—results of the PPAR Study
2007
Vascular injury and modulation of MAPKs: A targeted approach to therapy of restenosis
2007
Regulation of Adaptive Immunity in Health and Disease by Cholesterol Metabolism
2015
CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity
2009 Standout
Simple Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell Identities
2010 Standout
Mechanisms linking obesity to insulin resistance and type 2 diabetes
2006 StandoutNature
The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease
2011 Standout
The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality
2008
PPARγ signaling and metabolism: the good, the bad and the future
2013 Standout
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
2013 StandoutNobel
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
2010 Standout
Sterile inflammation: sensing and reacting to damage
2010 Standout
Progress and challenges in translating the biology of atherosclerosis
2011 StandoutNature
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
2012 Standout
Macrophage biology in development, homeostasis and disease
2013 StandoutNature
Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis
2011 Standout
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
2010 Standout
Stabilisation of atherosclerotic plaques
2011
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
2013 Standout
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis†
2007
Obesity induces a phenotypic switch in adipose tissue macrophage polarization
2007 Standout
Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters
2009 Standout
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 Standout
Pathophysiology of Human Visceral Obesity: An Update
2013 Standout
Angiopoietin-like 4 is a potent angiogenic factor and a novel therapeutic target for patients with proliferative diabetic retinopathy
2015 StandoutNobel
Measurement of the High–Molecular Weight Form of Adiponectin in Plasma Is Useful for the Prediction of Insulin Resistance and Metabolic Syndrome
2006
Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome
2006 Standout
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
2008 Standout
Mechanisms of Insulin Action and Insulin Resistance
2018 Standout
Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals
2014 Standout
VEGF Secreted by Hypoxic Müller Cells Induces MMP-2 Expression and Activity in Endothelial Cells to Promote Retinal Neovascularization in Proliferative Diabetic Retinopathy
2013 StandoutNobel
Regulation of Macrophage Functions by PPAR-α, PPAR-γ, and LXRs in Mice and Men
2008
Fat and Beyond: The Diverse Biology of PPARγ
2008 Standout
Metformin Inhibits Proinflammatory Responses and Nuclear Factor-κB in Human Vascular Wall Cells
2005
Peroxisome Proliferator-Activated Receptor γ and Adipose Tissue—Understanding Obesity-Related Changes in Regulation of Lipid and Glucose Metabolism
2006
Human serum leads to differentiation of human hepatoma cells, restoration of very-low-density lipoprotein secretion, and a 1000-fold increase in HCV Japanese fulminant hepatitis type 1 titers
2013 StandoutNobel
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.
2007
Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk
2017
Augmentation of Myocardial Production of 15-Epi-Lipoxin-A 4 by Pioglitazone and Atorvastatin in the Rat
2006
Inflammatory Mechanisms in Obesity
2011 Standout
Mechanisms of Diabetic Complications
2013 Standout
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Liver X receptor and peroxisome proliferator‐activated receptor as integrators of lipid homeostasis and immunity
2012
Effects of Pioglitazone on Lipoproteins, Inflammatory Markers, and Adipokines in Nondiabetic Patients with Metabolic Syndrome
2005
Insulin Resistance and Atherosclerosis
2006
Cardiovascular safety of sulfonylureas: a meta‐analysis of randomized clinical trials
2013
Works of Daniel Walcher being referenced
LXR activation inhibits chemokine-induced CD4-positive lymphocyte migration
2010
Improvement of Cardiovascular Risk Markers by Pioglitazone Is Independent From Glycemic Control
2005
Telmisartan Inhibits CD4-Positive Lymphocyte Migration Independent of the Angiotensin Type 1 Receptor via Peroxisome Proliferator-Activated Receptor-γ
2007
Pioglitazone Reduces Neointima Volume After Coronary Stent Implantation
2005
Effect of Rosiglitazone Treatment on Plaque Inflammation and Collagen Content in Nondiabetic Patients
2006
C-Peptide Colocalizes with Macrophages in Early Arteriosclerotic Lesions of Diabetic Subjects and Induces Monocyte Chemotaxis In Vitro
2004
Rapid Effects of Rosiglitazone Treatment on Endothelial Function and Inflammatory Biomarkers
2005
C-Peptide Induces Chemotaxis of Human CD4-Positive Cells
2004
Thiazolidinediones Reduce Endothelial Expression of Receptors for Advanced Glycation End Products
2004
LXR Activation Reduces Proinflammatory Cytokine Expression in Human CD4-Positive Lymphocytes
2006